TwinBeech Capital’s Editas Medicine EDIT Stock Holding History

TwinBeech Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-80,974	Closed	-$991K	–	751
2022 Q3	$991K	Buy	+80,974	New	+$1.26M	0.03%	458
2021 Q4	–	Sell	-37,184	Closed	-$1.53M	–	623
2021 Q3	$1.53M	Buy	+37,184	New	+$2.04M	0.11%	255
2021 Q2	–	Sell	-12,550	Closed	-$527K	–	490
2021 Q1	$527K	Buy	+12,550	New	+$715K	0.08%	295

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TwinBeech Capital's EDIT Position: Q4 2022 in Review

TwinBeech Capital sold out of Editas Medicine (EDIT) in Q4 2022, closing a stake of 80,974 shares — an estimated $991K sold.

TwinBeech Capital first reported a position in EDIT in Q1 2021 and held it in 3 quarters. The position peaked at $1.53M in Q3 2021. 250 funds tracked by Wall St. Rank hold EDIT as of Q4 2022.

TwinBeech Capital reported no remaining Editas Medicine position as of Q4 2022 after selling out during the quarter.
TwinBeech Capital sold 80,974 Editas Medicine shares in Q4 2022, an estimated $991K.
TwinBeech Capital first reported a position in Editas Medicine in Q1 2021 and held it in 3 quarters.
TwinBeech Capital's Editas Medicine position peaked at $1.53M in Q3 2021.
250 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2022.

Based on TwinBeech Capital's 13F filing for Q4 2022, filed 14 Feb 2023.